AMZ30

AMZ30 is selective protein phosphatase methylesterase-1 (PME-1) inhibitor with IC50s of 600 nM and 3.5 µM in human cell lysates and in HEK 293T cells, respectively. AMZ30 shows >100-fold selectivity relative to other serine hydrolases. AMZ30 reduces the demethylated form of PP2A in living cells. AMZ30 attenuates muscle cell differentiation. AMZ30 increases the resistance of U87MG and U251MG glioblastoma cells to t-BHP-induced oxidative stress. AMZ30can be used for the study of glioblastoma[1][2][3].

Product Specifications

CAS Number

[1313613-09-0]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Akt; ERK; Phosphatase

Type

Reference compound

Related Pathways

MAPK/ERK Pathway; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Stem Cell/Wnt

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/AMZ30.html

Purity

99.76

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=S(C1=CC([N+]([O-])=O)=CC=C1)(N2C(/C=C(S(=O)(C3=CC=C(F)C=C3)=O)\C#N)=CC=C2)=O

Molecular Formula

C19H12FN3O6S2

Molecular Weight

461.44

Precautions

H302, H315, H319, H335

References & Citations

[1]Labuzan SA, et al. Inhibition of protein phosphatase methylesterase 1 dysregulates MAP kinase signaling and attenuates muscle cell differentiation. Gene. 2020 May 20;739:144515.|[2]Guffens L, et al. PME-1 sensitizes glioblastoma cells to oxidative stress-induced cell death by attenuating PP2A-B55α-mediated inactivation of MAPKAPK2-RIPK1 signaling. Cell Death Discov. 2023 Jul 27;9 (1) :265.|[3]Bachovchin DA, et al. Discovery and optimization of sulfonyl acrylonitriles as selective, covalent inhibitors of protein phosphatase methylesterase-1. J Med Chem. 2011 Jul 28;54 (14) :5229-36.